GlassScriptPhysician profile
Hilary A Beaver
NPI 1417958869
$6,494.65
in general payments reported to CMS, 2019-2025
31 companies · $931 in 2025
The $931 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $209 · 2021: $316 · 2022: $465 · 2023: $973 · 2024: $3,225 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,029 · Consulting Fee: $2,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,028.77 |
| Consulting Fee | $2,100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,953.73 | 2024-2025 | Tepezza, Uplizna |
| Horizon Therapeutics Plc | $545.48 | 2020-2023 | Tepezza, Uplizna |
| Alcon Vision LLC | $404.89 | 2019-2025 | Clareon, Tryptyr, Rocklatan |
| Sun Pharmaceutical Industries INC. | $388.75 | 2019-2025 | Cequa |
| Ocular Therapeutix, INC. | $235.62 | 2019-2025 | Dextenza |
| Glaukos Corporation | $234.57 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $219.00 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $179.31 | 2022-2025 | Ozurdex, Vuity, Lumigan |
| Alexion Pharmaceuticals, INC. | $167.43 | 2022-2025 | Ultomiris |
| Oyster Point Pharma, INC. | $157.00 | 2022-2024 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $145.40 | 2019-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $139.05 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $83.85 | 2019-2021 | |
| Shire North American Group INC | $82.93 | 2019 | |
| Penumbra, INC. | $74.22 | 2024 | Penumbra Coil 400 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $66.94 | 2021 | |
| Aerie Pharmaceuticals, INC. | $57.88 | 2019-2020 | |
| Ucb, INC. | $48.31 | 2025 | Rystiggo |
| Biotissue Holdings INC. | $36.51 | 2022 | |
| Apellis Pharmaceuticals, INC. | $34.45 | 2022-2023 | |
| Ivantis, INC | $30.37 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $30.05 | 2021-2024 | Tecnis Simplicity |
| Tarsus Pharmaceuticals, INC. | $28.66 | 2025 | Xdemvy |
| Genentech USA, INC. | $22.71 | 2024 | Vabysmo |
| Kala Pharmaceuticals, INC. | $20.36 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Eyepoint US, INC. | $18.62 | 2019 | |
| Eyevance Pharmaceuticals LLC | $17.84 | 2020 | |
| Omeros Corporation | $17.77 | 2019 | |
| Merz North America, INC. | $17.29 | 2019 | |
| Allergan, INC. | $16.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hilary Beaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.